baricitinib + digoxin

This is a **combination of two pharmaceutical drugs, baricitinib and digoxin**. Baricitinib is an oral, small molecule Janus kinase (JAK) inhibitor primarily acting on JAK1 and JAK2, approved for the treatment of moderate to severe rheumatoid arthritis, atopic dermatitis, alopecia areata, and COVID-19 in hospitalized adults. Its action suppresses inflammation by preventing phosphorylation events in cytokine signaling pathways. Digoxin is a cardiac glycoside used in the management of atrial fibrillation and heart failure, acting primarily by inhibiting the sodium-potassium ATPase enzyme, which increases intracellular calcium and enhances cardiac contractility while controlling heart rate. There is no evidence that this drug combination under the name "baricitinib + digoxin" has been formulated or approved as a unique product. If these drugs are co-administered, no approved fixed-dose combination or unique formulation is marketed; the entry is a combination of the two active substances for clinical or pharmacological consideration only.